Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01154621 · ClinicalTrials.gov registry record · Phase 1

Assessing the Safety and Tolerability of a Single IV Dose of AZD9742 in Healthy Elderly Male and Female Subjects

A Phase 1 study, sponsored by AstraZeneca.

Completed
Registry status
Phase 1
Development phase
12
Enrollment target

NCT01154621 is a Phase 1 study that has completed, run by AstraZeneca. The registered enrollment target is 12 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01154621, a Phase 1 study, has completed, sponsored by AstraZeneca.

COMPLETED
Registry status
Phase 1
Development phase
12 participants
Enrollment target

Study Summary

The aim of this study is to examine the safety and tolerability of a single dose of AZD9742 in elderly individuals.

Interventions

  • DRUG Placebo
  • DRUG AZD9742

Trial Details

FieldValue
Enrollment Target 12 participants
Start Date 2010-06
Est. Completion 2010-07
Phase Phase 1

Sponsor

AstraZeneca

1,285 total trials

What the Registry Record Tells You About NCT01154621

The ClinicalTrials.gov registry entry for NCT01154621 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.

NCT01154621 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT01154621 about?

NCT01154621 is a clinical study titled "Assessing the Safety and Tolerability of a Single IV Dose of AZD9742 in Healthy Elderly Male and Female Subjects". The aim of this study is to examine the safety and tolerability of a single dose of AZD9742 in elderly individuals.

What is the current status of trial NCT01154621?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 12 participants. The study started on 2010-06. Estimated completion is 2010-07.

What interventions are being tested in trial NCT01154621?

The interventions under investigation include: Placebo (DRUG), AZD9742 (DRUG).

Who is sponsoring clinical trial NCT01154621?

This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.